Portola Pharmaceuticals (NASDAQ:PTLA) and iCo Therapeutics (OTCMKTS:ICOTF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
This table compares Portola Pharmaceuticals and iCo Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Portola Pharmaceuticals and iCo Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Portola Pharmaceuticals currently has a consensus target price of $35.00, indicating a potential upside of 143.56%. Given Portola Pharmaceuticals’ higher possible upside, equities analysts plainly believe Portola Pharmaceuticals is more favorable than iCo Therapeutics.
Valuation and Earnings
This table compares Portola Pharmaceuticals and iCo Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Portola Pharmaceuticals||$40.13 million||27.87||-$350.22 million||($5.01)||-2.87|
|iCo Therapeutics||N/A||N/A||-$1.30 million||N/A||N/A|
iCo Therapeutics has lower revenue, but higher earnings than Portola Pharmaceuticals.
Volatility & Risk
Portola Pharmaceuticals has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, iCo Therapeutics has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500.
Portola Pharmaceuticals beats iCo Therapeutics on 5 of the 8 factors compared between the two stocks.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
About iCo Therapeutics
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Portola Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Portola Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.